Q1 2025 Recordati Industria Chimica e Farmaceutica SpA Earnings Call Transcript
Key Points
- Recordati SpA (RCDTF) reported a net revenue of $680 million for Q1 2025, marking an 11.9% increase compared to the previous year.
- The company's specialty and primary care business saw a 5% growth, while the rare disease business grew by 11.5% on a like-for-like basis at constant exchange rates.
- Recordati SpA (RCDTF) achieved an EBITDA margin of 39.7%, demonstrating robust top-line performance and operating leverage.
- The company received timely FDA approval for the label extension of Syriza into Cushing's syndrome in the US, enhancing its market potential.
- Recordati SpA (RCDTF) confirmed its full-year 2025 financial targets and expects continued positive momentum, projecting double-digit growth across key financial metrics by 2027.
- The company faced increased finance expenses and a higher tax rate, which partially offset higher operating income.
- Sales of Avodart combo were softer, particularly in Spain and the Andalusia region.
- The cough and cold season was weaker than expected in Russia and Turkey, impacting sales in those regions.
- Forex headwinds are expected to create challenges, although the company remains committed to margin accretion versus 2024.
- The net financial expenses were above the expected rate, influenced by FX volatility and non-monetary losses.
Good afternoon. This is the conference operator. Welcome and thank you for joining the first quarter 2025 results conference call.
(Operator Instructions)
At this time, I would like to turn a conference over to Ms. Eugenia Litz, Vice President of Investor Relations of Recordati. Please go ahead, madam.
Thank you and good afternoon, everyone. I'm pleased to be here today with Robert Koremans, our CEO and Luigi Corte, our CFO. Together they will present results for the first quarter of 2025. Also joining for the Q&A session will be Alberto Martinez, Executive Vice President of specialty in primary care, Scott Pescatore, Executive Vice President of Rare Diseases, and Milan Draskovic, executive Vice President of R&D. As always, the presentation is available in the investor section of our website. It is now my pleasure to pass the call over to Rob. Please go ahead.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
